There has been no new development with regards to Endonovo Therapeutics Inc (OTCMKTS:ENDV) for many months but that has not taken the company out of the radars of investors. Yesterday, the Endonovo stock was in sharp focus among investors and ended the day with gains of as much as 85%.
While the rally in the stock may appear speculative in nature, it might still be a good idea for investors to take a look at a major development with regards to Endonovo back in May this year. Back on May 11 the company announced that it had completed the shipment of the SofPulse® tPEMF Devices for the purposes of the Orthopedic Shoulder and Knee Study sponsored by Stanford University.
The study is titled ‘Pulsed Electromagnetic Field (PEMF) Therapy for Post-operative Pain Following Orthopedic Surgery’ and is going to be completed at some point in August next year. The devices from Endonovo are going to help in reducing the pain and edema in patients following a procedure.
The devices have been approved by the United States Food and Drug Administration. While it may be unlikely that the rally on Wednesday was triggered by this, it is something that investors ought to know about.
